{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:13:48Z","timestamp":1786986828096,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clgc.2026.102536","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:59:58Z","timestamp":1773075598000},"page":"102536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Androgen Deprivation Therapy\u2013Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"given":"Alicia K","family":"Morgans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sentana-Lledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Wildgust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102536_bib0001","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433126","article-title":"Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management","volume":"44","author":"Gudenkauf","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2026.102536_bib0002","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0003","unstructured":"EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer. Guidelines: prostate cancer. Available at: https:\/\/uroweb.org\/guidelines\/prostate-cancer. Accessed: April 29, 2025."},{"key":"10.1016\/j.clgc.2026.102536_bib0004","doi-asserted-by":"crossref","first-page":"R297","DOI":"10.1530\/ERC-17-0153","article-title":"Estradiol for the mitigation of adverse effects of androgen deprivation therapy","volume":"24","author":"Russell","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clgc.2026.102536_bib0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clgc.2026.102536_bib0006","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.urolonc.2009.09.004","article-title":"Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States","volume":"29","author":"Gilbert","year":"2011","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0007","article-title":"Management of prostate cancer in older adults","volume":"43","author":"Graham","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2026.102536_bib0008","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s13063-023-07325-w","article-title":"A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2)","volume":"24","author":"Crabb","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.clgc.2026.102536_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.maturitas.2009.10.017","article-title":"Managing hot flushes in men after prostate cancer \u2013 a systematic review","volume":"65","author":"Frisk","year":"2010","journal-title":"Maturitas"},{"key":"10.1016\/j.clgc.2026.102536_bib0010","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/cncr.31024","article-title":"Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: the role of hot flashes and nocturia","volume":"124","author":"Gonzalez","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102536_bib0011","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/aja.2011.101","article-title":"Androgen deprivation therapy-associated vasomotor symptoms","volume":"14","author":"Jones","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.clgc.2026.102536_bib0012","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","article-title":"Management of complications of androgen deprivation therapy in the older man","volume":"70","author":"Mohile","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2026.102536_bib0013","first-page":"e107","article-title":"Management of androgen deprivation therapy-associated hot flashes in men with prostate cancer","volume":"46","author":"Qan'ir","year":"2019","journal-title":"Oncol Nurs Forum"},{"key":"10.1016\/j.clgc.2026.102536_bib0014","doi-asserted-by":"crossref","DOI":"10.14440\/jbm.2024.0019","article-title":"Side effects of prostate cancer therapies and potential management","volume":"11","author":"Xiao","year":"2024","journal-title":"J Biol Methods"},{"key":"10.1016\/j.clgc.2026.102536_bib0015","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2026.102536_bib0016","doi-asserted-by":"crossref","first-page":"S1258","DOI":"10.1016\/j.annonc.2024.08.2312","article-title":"LBA69 Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer","volume":"35","author":"Langley","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0017","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/cancers14071784","article-title":"Prostate cancer and sleep disorders: a systematic review","volume":"14","author":"Sparasci","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102536_bib0018","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3390\/healthcare10050832","article-title":"Evaluating patterns and factors related to sleep disturbances in prostate cancer patients","volume":"10","author":"Mondal","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"10.1016\/j.clgc.2026.102536_bib0019","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco","year":"2023","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.euros.2024.03.003","article-title":"Fatigue in prostate cancer: a roundtable discussion and thematic literature review","volume":"63","author":"Cornford","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102536_bib0021","first-page":"4159","article-title":"Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison","volume":"24","author":"Nelson","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2026.102536_bib0022","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/cncr.33397","article-title":"Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: preliminary findings","volume":"127","author":"Hoogland","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2026.102536_bib0023","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/pros.24676","article-title":"Development of depression in patients using androgen deprivation therapy: a systemic review and meta-analysis","volume":"84","author":"Qazi","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102536_bib0024","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2015.64.1969","article-title":"Association of androgen deprivation therapy with depression in localized prostate cancer","volume":"34","author":"Dinh","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0025","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.euf.2019.11.010","article-title":"Androgen deprivation therapy and mental health: impact on depression and cognition","volume":"6","author":"Izard","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102536_bib0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.mce.2017.08.001","article-title":"Role of the androgen receptor in the central nervous system","volume":"465","author":"Mhaouty-Kodja","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.clgc.2026.102536_bib0027","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13293-020-00309-4","article-title":"Androgens' effects on cerebrovascular function in health and disease","volume":"11","author":"Abi-Ghanem","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.clgc.2026.102536_bib0028","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41391-019-0195-5","article-title":"A review of prostate cancer treatment impact on the CNS and cognitive function","volume":"23","author":"Ryan","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102536_bib0029","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.exger.2004.06.019","article-title":"Low free testosterone is an independent risk factor for Alzheimer's disease","volume":"39","author":"Hogervorst","year":"2004","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.clgc.2026.102536_bib0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.maturitas.2011.05.012","article-title":"Testosterone levels and cognition in elderly men: a review","volume":"69","author":"Holland","year":"2011","journal-title":"Maturitas"},{"key":"10.1016\/j.clgc.2026.102536_bib0031","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tics.2005.12.010","article-title":"Thinking with your gonads: testosterone and cognition","volume":"10","author":"Janowsky","year":"2006","journal-title":"Trends Cogn Sci"},{"key":"10.1016\/j.clgc.2026.102536_bib0032","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12035-015-9315-y","article-title":"Low testosterone level and risk of Alzheimer's disease in the elderly men: a systematic review and meta-analysis","volume":"53","author":"Lv","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.clgc.2026.102536_bib0033","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1212\/01.WNL.0000106840.72938.84","article-title":"Plasma testosterone levels in Alzheimer and Parkinson diseases","volume":"62","author":"Okun","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clgc.2026.102536_bib0034","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000094199.60829.F5","article-title":"Low androgenization index in elderly women and elderly men with Alzheimer's disease","volume":"62","author":"Paoletti","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clgc.2026.102536_bib0035","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1200\/JCO.2014.60.1963","article-title":"Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison","volume":"33","author":"Gonzalez","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0036","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1200\/JCO.2015.63.6266","article-title":"Androgen deprivation therapy and future Alzheimer's disease risk","volume":"34","author":"Nead","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0037","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.6562","article-title":"Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer","volume":"2","author":"Jayadevappa","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102536_bib0038","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1200\/JCO.2016.69.6203","article-title":"Androgen deprivation therapy and the risk of dementia in patients with prostate cancer","volume":"35","author":"Khosrow-Khavar","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0039","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2017.72.6109","article-title":"Risk of Alzheimer's disease among senior Medicare beneficiaries treated with androgen deprivation therapy for prostate cancer","volume":"35","author":"Baik","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0040","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/jamaoncol.2018.4423","article-title":"Association of androgen deprivation therapy with dementia in men with prostate cancer who receive definitive radiation therapy","volume":"4","author":"Deka","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0041","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/JU.0000000000001341","article-title":"The risk of new onset dementia and\/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis","volume":"205","author":"Sari Motlagh","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0042","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"181","author":"Saylor","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0043","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2010.03942.x","article-title":"Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy","volume":"74","author":"Hamilton","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clgc.2026.102536_bib0044","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2022.09.008","article-title":"The burden of uncontrolled cardiovascular risk factors in men with prostate cancer: a RADICAL-PC analysis","volume":"5","author":"Klimis","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0045","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0046","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0047","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bju.13203","article-title":"Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events","volume":"118","author":"Schmid","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2026.102536_bib0048","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0049","unstructured":"Patel S, Yadalam A, van Assen M, et al. SUO 2025: coronary artery plaque progression after androgen deprivation therapy in men with prostate cancer: a randomized controlled trial comparing relugolix versus leuprolide. Available at: https:\/\/suo-abstracts.secure-platform.com\/a\/gallery\/rounds\/24\/details\/4356. Accessed: March 30, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0050","article-title":"Coronary plaque progression after androgen deprivation therapy in men with prostate cancer: a randomized clinical trial","author":"Patel","year":"2026","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.clgc.2026.102536_bib0051","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2013.10.007","article-title":"Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer","volume":"133","author":"Toukh","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.clgc.2026.102536_bib0052","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5489\/cuaj.3936","article-title":"Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: a prospective, longitudinal study","volume":"11","author":"Kaur","year":"2017","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2026.102536_bib0053","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41388-024-03024-1","article-title":"PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression","volume":"43","author":"Li","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2026.102536_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2022.0334","article-title":"Cardiovascular complications of treatment for prostate cancer","volume":"83","author":"Ferreira","year":"2022","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.clgc.2026.102536_bib0055","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.clgc.2026.102536_bib0056","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","article-title":"Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement","volume":"33","author":"Resnick","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0057","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0058","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102536_bib0059","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-5347(05)00033-9","article-title":"Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer","volume":"175","author":"Smith","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0060","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","article-title":"Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0061","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5534\/wjmh.210061","article-title":"Multidisciplinary consensus on the prevention and treatment of osteoporosis and fragility fractures in patients with prostate cancer receiving androgen-deprivation therapy","volume":"40","author":"Casado","year":"2022","journal-title":"World J Mens Health"},{"key":"10.1016\/j.clgc.2026.102536_bib0062","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11914-019-00536-8","article-title":"Bone health in men with prostate cancer: review article","volume":"17","author":"El Badri","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.clgc.2026.102536_bib0063","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102536_bib0064","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102536_bib0065","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.juro.2016.12.022","article-title":"Risks of serious toxicities from intermittent versus continuous androgen deprivation therapy for advanced prostate cancer: a population based study","volume":"197","author":"Tsai","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0066","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2490-14-9","article-title":"Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis","volume":"14","author":"Botrel","year":"2014","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0067","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0068","doi-asserted-by":"crossref","first-page":"727","DOI":"10.6004\/jnccn.2014.0074","article-title":"Intermittent versus continuous androgen deprivation therapy","volume":"12","author":"Higano","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2026.102536_bib0069","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0070","unstructured":"ClinicalTrials.gov. Stereotactic body radiotherapy with or without darolutamide for oligorecurrent prostate cancer (DART). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04641078. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0071","unstructured":"ClinicalTrials.gov. Radioablation with or without androgen deprivation therapy in metachronous prostate cancer oligometastasis (RADIOSA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT03940235. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0072","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0073","unstructured":"ClinicalTrials.gov. Metastasis-directed therapy for oligorecurrent prostate cancer (SPARKLE). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05352178. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0074","unstructured":"ClinicalTrials.gov. Androgen deprivation therapy for oligo-recurrent prostate cancer in addition to radiotherapy (ADOPT). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04302454. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0075","unstructured":"ClinicalTrials.gov. 177-Lutetium-PSMA before stereotactic body radiotherapy for the treatment of oligorecurrent prostate cancer, the LUNAR study (LUNAR). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05496959. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0076","unstructured":"ClinicalTrials.gov. Radium-223 and SABR versus SABR for oligometastatic prostate cancers (RAVENS). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04037358. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0077","unstructured":"ClinicalTrials.gov. Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (Bullseye). Available at: https:\/\/clinicaltrials.gov\/study\/NCT04443062. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0078","doi-asserted-by":"crossref","first-page":"S1631","DOI":"10.1016\/j.annonc.2025.09.106","article-title":"LBA90 Prospective randomized phase II trial of 177Lutetium-PSMA therapy neoadjuvant to stereotactic ablative radiotherapy for recurrent oligo-metastatic hormone-sensitive prostate cancer (LUNAR NCT05496959)","volume":"36","author":"Calais","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0079","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1200\/JCO.2025.43.16_suppl.5009","article-title":"Lutetium-177-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE trial)","volume":"43","author":"Priv\u00e9","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0080","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0081","unstructured":"ClinicalTrials.gov. Testing interruption of hormonal medications in patients responding exceptionally to therapy for metastatic prostate cancer (A-DREAM). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05241860. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0082","unstructured":"ClinicalTrials.gov. Intermittent androgen deprivation therapy in the era of AR pathway inhibitors. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05974774. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0083","unstructured":"ClinicalTrials.gov. A study of an intermittent ADT approach with apalutamide monotherapy in participants with mCSPC (LIBERTAS). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05884398. Accessed: January 21, 2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0084","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU - EANM - ESTRO - ESUR - ISUP - SIOG guidelines on prostate cancer","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0085","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0086","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.8751","article-title":"Enzalutamide and prostate-specific antigen levels in metastatic prostate cancer: a secondary analysis of the ARCHES randomized clinical trial","volume":"8","author":"Azad","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102536_bib0087","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0088","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102536_bib0089","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0090","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102536_bib0091","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0092","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0093","doi-asserted-by":"crossref","first-page":"TPS236","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS236","article-title":"Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design","volume":"42","author":"Azad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0094","doi-asserted-by":"crossref","first-page":"TPS232","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS232","article-title":"EORTC GUCG 2238 De-escalate: a pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naive prostate cancer in the era of new AR pathway inhibitors","volume":"42","author":"Grisay","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0095","doi-asserted-by":"crossref","first-page":"TPS5118","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5118","article-title":"A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM\/Alliance A032101)","volume":"42","author":"Choudhury","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0096","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102536_bib0097","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-020-15424-4","article-title":"Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation","volume":"11","author":"Brady-Nicholls","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2026.102536_bib0098","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.euf.2025.11.015","article-title":"Strategies to mitigate breast-related adverse events in patients with high-risk biochemically recurrent prostate cancer receiving enzalutamide monotherapy: perspectives and challenges","volume":"12","author":"Shore","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102536_bib0099","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2025.01.001","article-title":"Incidence, management, and prevention of gynecomastia and breast pain in patients with prostate cancer undergoing antiandrogen therapy: a systematic review and meta-analysis of randomized controlled trials","volume":"73","author":"Tsuboi","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102536_bib0100","unstructured":"Swerdloff RS., Ng JCM. Gynecomastia: etiology, diagnosis, and treatment. In: Feingold K.R., Adler R.A., Ahmed S.F., eds., et al. Endotext. South Dartmouth (MA): MDText.com; 2000-2026."},{"key":"10.1016\/j.clgc.2026.102536_bib0101","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2025.43.5_suppl.147","article-title":"Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC)","volume":"43","author":"Azad","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0102","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1391825","article-title":"EORTC 2238 \"De-Escalate\": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors","volume":"14","author":"Grisay","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102536_bib0103","unstructured":"Sayyid R ASCO 2024: A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM\/Alliance A032101). Available at: https:\/\/www.urotoday.com\/conference-highlights\/asco-2024\/asco-2024-prostate-cancer\/152503-asco-2024-a-phase-2-trial-of-adt-interruption-in-patients-responding-exceptionally-to-ar-pathway-inhibitor-in-metastatic-hormone-sensitive-prostate-cancer-a-dream-alliance-a032101.html. Accessed: July 15, 2025."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T19:45:20Z","timestamp":1779997520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1558767326000364"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102536","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Androgen Deprivation Therapy\u2013Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102536","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102536"}}